# Druggability Assessment of EC Layer II Therapeutic Hypotheses
## HYPOTHESIS 3: Reelin-Mediated Cytoskeletal Stabilization (Revised Confidence: 0.55)
### Druggability Assessment: **MODERATE-LOW**
**Target:** RELN pathway (Reelin, DAB1, LIS1)
**Chemical Matter Challenges:**
- Reelin is a large extracellular matrix protein (3461 amino acids) - not directly druggable with small molecules
- Must target downstream signaling (ApoER2/VLDLR receptors, DAB1 phosphorylation)
- Blood-brain barrier penetration required for central targets
**Existing Compounds:**
- **None in clinical development** for reelin pathway
- Research tools: Reelin antibodies (non-CNS penetrant)
- **CGP-37157** (indirect, affects calcium signaling downstream)
**Competitive Landscape:**
- **Vacant field** - no major pharma programs targeting reelin
- Academic interest only (University of California, Rockefeller University groups)
**Development Strategy:**
- Small molecule enhancers of DAB1 phosphorylation
- Allosteric modulators of ApoER2/VLDLR
- Gene therapy approaches (AAV-RELN)
**Cost Estimate:** $50-75M over 8-10 years
**Timeline:** 10+ years to clinical proof-of-concept
**Safety Concerns:** Developmental pathway - risk of off-target effects on neuroplasticity
---
## HYPOTHESIS 6: Tau-Independent Microtubule Stabilization via MAP6 (Revised Confidence: 0.45)
### Druggability Assessment: **MODERATE**
**Target:** MAP6/STOP protein
**Chemical Matter:**
- **Existing microtubule stabilizers:** Paclitaxel analogs, epothilones
- **BBB-penetrant options:** **TPI-287** (abeotaxane), **ABI-274**
- Novel MAP6-specific enhancers needed
**Existing Clinical Candidates:**
- **TPI-287** (Cortice Biosciences) - Phase I completed for AD (NCT01966666)
- Results: Well-tolerated, some biomarker improvements
- Company status: Acquired by Signal Therapeutics 2019
- **ABI-274** (AbbVie/Arbutus) - discontinued 2018
**Competitive Landscape:**
- **Moderate competition** in microtubule stabilization space
- **Active players:** AnTau Therapeutics (posidazenatide), AC Immune (anti-tau antibodies)
- **Major pharma interest:** Roche (semorinemab), Biogen (BIIB092)
**Development Path:**
1. MAP6-selective small molecule screening (18-24 months, $3-5M)
2. Lead optimization (2-3 years, $10-15M)
3. IND-enabling studies (1.5 years, $8-12M)
4. Phase I safety (1.5 years, $15-20M)
**Total Cost:** $40-55M over 6-8 years
**Safety Concerns:** Peripheral neuropathy (paclitaxel class effect), potential motor dysfunction
---
## HYPOTHESIS 1: HCN1 Channel Enhancement (Revised Confidence: 0.35)
### Druggability Assessment: **HIGH**
**Target:** HCN1 channels
**Chemical Matter:**
- **Established pharmacology:** Well-characterized ion channel
- **Existing enhancers:** Lamotrigine (weak), DK-AH 269 (research tool)
- **Structure available:** Cryo-EM structures published 2018-2020
**Existing Programs:**
- **No current clinical programs** for HCN1 enhancement in AD
- **Historical context:** Most HCN modulators are blockers (ivabradine for heart failure)
- **Research compounds:** ML133 (positive allosteric modulator)
**Competitive Landscape:**
- **Limited direct competition** for HCN1 enhancement
- **Adjacent space:** Kv7 channel modulators (Xenon Pharmaceuticals XEN901)
- **Ion channel expertise:** Icagen, Xenon, Biohaven
**Development Requirements:**
- Selective HCN1 vs HCN2/3/4 enhancement
- CNS penetration with minimal cardiac effects
- Dose-limiting toxicity likely seizures/arrhythmias
**Cost:** $60-80M over 7-9 years
**Major Risk:** Excitotoxicity and proarrhythmic effects
**Regulatory Path:** Likely requires cardiac safety package
---
## HYPOTHESIS 4: Perforant Path Protection (PGC-1α/KIF5A) (Revised Confidence: 0.40)
### Druggability Assessment: **MODERATE-HIGH**
**Target 1: PGC-1α Enhancement**
**Existing Compounds:**
- **ZLN005** (activator) - research stage only
- **Metformin** (indirect activation) - generic, well-characterized
- **Bezafibrate** (PPARα agonist, upstream) - approved drug
**Target 2: KIF5A Enhancement**
**Chemical Matter:**
- **Very challenging** - motor proteins difficult to drug
- No existing enhancers in development
- Alternative: enhance cargo loading (JIP proteins)
**Clinical Programs:**
- **Metformin in AD:** Multiple trials ongoing
- **NCT04098666** (University of Pennsylvania) - Phase II/III
- **NCT02432287** (Washington University) - completed
- **PPAR agonists:** Historical failures (rosiglitazone), but new interest
**Competitive Landscape:**
- **Crowded metabolic field:** Numerous diabetes drugs being repurposed
- **Key players:** Novo Nordisk (semaglutide CNS trials), Lilly (solanezumab + metabolic)
**Development Strategy:**
1. **Repurposing approach:** Metformin extended-release CNS formulation
2. **Novel PGC-1α activators:** Partner with metabolic disease companies
3. **Combination therapy:** Metabolic enhancer + neuroprotective
**Cost:** $25-40M (repurposing) vs $70-100M (novel compound)
**Timeline:** 4-6 years (repurposing) vs 8-10 years (novel)
**Safety:** Well-characterized for metformin; novel compounds require full development
---
## HYPOTHESIS 2: MCU Modulation (Revised Confidence: 0.25) - **NOT RECOMMENDED**
### Druggability: **HIGH** (but inadvisable)
**Rationale for rejection:**
- **High toxicity risk:** MCU enhancement could cause mitochondrial calcium overload
- **Contradictory evidence:** MCU inhibition, not enhancement, may be protective
- **Existing MCU inhibitors:** Ruthenium Red, DS16570511 (research tools)
- **No enhancement programs:** All clinical interest in MCU inhibition
---
## HYPOTHESIS 5: IDH2 Enhancement (Revised Confidence: 0.30) - **NOT RECOMMENDED**
### Druggability: **MODERATE** (but inadvisable)
**Rationale for rejection:**
- **Oncogenic risk:** IDH2 mutations associated with leukemia/glioma
- **Existing programs focus on inhibition:** Enasidenib (FDA approved for IDH2 mutant AML)
- **Companies:** Agios Pharmaceuticals, Celgene/BMS
- **Enhancement approach:** Contrary to established cancer biology
---
## HYPOTHESIS 7: Lactate Shuttle Enhancement (Revised Confidence: 0.35) - **LIMITED POTENTIAL**
### Druggability: **MODERATE**
**Targets:** MCT1/MCT2 transporters
**Existing Research:**
- **AR-C155858** (MCT1 inhibitor) - opposite direction
- **MCT2 enhancers:** Limited chemical matter available
- **Lactate supplementation:** Simple approach, safety concerns
**Issues:**
- **Lactate toxicity:** Acidosis, inflammation risk
- **Limited evidence:** Astrocyte-neuron lactate shuttle controversial
- **No clinical programs:** MCT modulation for neurodegeneration
---
## OVERALL RECOMMENDATION RANKING:
### 1. **MAP6/Microtubule Stabilization** - Proceed with caution
- **Established druggability** with existing clinical precedent (TPI-287)
- **Moderate competition** but differentiated approach
- **Clear development path** and manageable costs
- **Key risk:** Peripheral toxicity management
### 2. **PGC-1α/Metabolic Enhancement** - Repurposing opportunity
- **Metformin repurposing** offers fastest, cheapest path
- **Strong clinical precedent** in diabetes/aging
- **Multiple ongoing trials** validate approach
- **Risk:** Efficacy may be limited in established disease
### 3. **Reelin Pathway** - Long-term research bet
- **Novel mechanism** with limited competition
- **High scientific interest** but challenging druggability
- **Gene therapy alternative** may be more feasible
- **Risk:** Long timeline, uncertain translatability
### **DO NOT PURSUE:** HCN1 enhancement (seizure/cardiac risks), MCU enhancement (toxicity), IDH2 enhancement (cancer risk), lactate shuttle (weak rationale)
**Recommended Strategy:** Portfolio approach combining MAP6 small molecules (3-4 year timeline) with metformin repurposing (immediate start) and reelin pathway research (10+ year horizon).